Review
Published on 02 Nov 2021
Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2021.731527
- 11,543 views
- 24 citations


